RECRUITINGINTERVENTIONAL

Ocular Blood Flow Imaging for Glaucoma Assessment

About This Trial

The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management. The main question it aims to answer are: * Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls? * Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring? Participants will be * measured for their blood pressure, heart rate, height, and weight * dilated with tropicamide * imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry * imaged using the XyCAM RI while inhaling 100% oxygen through a mask

Who May Be Eligible (Plain English)

Who May Qualify: - Age 18 and older with binocular vision - Able to provide willing to sign a consent form - Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria Who Should NOT Join This Trial: - The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar) - The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy - The subject has prior ocular disease other than glaucoma - The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye - The subject has more than 15 diopters of refractive error - The subject is a female who is pregnant or nursing - The subject has diabetes mellitus Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Age 18 and older with binocular vision * Able to provide informed consent * Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria Exclusion Criteria: * The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar) * The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy * The subject has prior ocular disease other than glaucoma * The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye * The subject has more than 15 diopters of refractive error * The subject is a female who is pregnant or nursing * The subject has diabetes mellitus

Treatments Being Tested

DEVICE

XyCAM with oxygen

After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.

Locations (1)

University of Maryland Eye Associates at Redwood

Baltimore, Maryland, United States